For health care professionals

For patients with gynecologic cancer, research shows that receiving treatment from a gynecologic oncologist right from the start improves patient outcomes. Does that mean every patient with gynecologic cancer needs to be treated full-time at a National Cancer Institute-designated cancer center, like the Fred Hutchinson Cancer Center? Not necessarily.

In an ongoing effort to develop cancer therapies that provide a better quality of life, Fred Hutchinson Cancer Center physicians are spearheading the next generation of cancer treatments that transform radiation therapy into precision medicine. This innovative strategy uses different types of radiation, such as X-rays, protons and neutrons, to trigger an immune response and enhance the effectiveness of immunotherapy. 

Fred Hutchinson Cancer Center leads the way when it comes to offering eligible patients alternative options when conventional therapies no longer work. With more than two dozen phase 1 clinical trials active at any given time, Fred Hutch is constantly poised to bring new cancer therapies from the bench to the bedside. For patients without other options, these trials offer potential access to promising treatments and an opportunity to help advance the science of cancer care. 

Nuclear medicine therapies, such as Lu-177 dotatate (Lutathera®), Lu-177 vipivotide tetraxetan, or Lu-177 PSMA (Pluvicto®) and radioiodine, are important tools for treating some types of cancer. Find out how Fred Hutch radiologists deliver nuclear medicine therapy and how to consult with specialists on your next case.